Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

Rodríguez‐Vida, Alejo; Maroto, Pablo; Font, Albert; Martîn, Cristina; Mellado, Begoña; Corbera, Alex; Orrillo, Mayra; Reig, Òscar; Querol, Rosa; Ríos-Hoyo, Alejandro; Cano, Laia Querol; Alonso, Judith; Martínez, Gemma; Galtes, Susana; Taus, Álvaro; Martinez-García, Maria; Juanpere, Núria; Juan, Ó.; Bellmunt, Joaquim

doi:10.1038/s41416-022-01991-4

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…149 DC vaccines can augment the immune response and improve tumor control with the help of ICI or adoptive T cells. 150,151 Numerous antigen peptide-DC vaccines are currently under development, and selecting peptides in the pool and their grouping for optimal efficacy should be given more attention. Customizing the neoantigen peptide pool is important to cover t tumor heterogeneity and enhance multiple tumor-specific target recognition.…”

Section: Cell-based Vaccinementioning

confidence: 99%

See 1 more Smart Citation

Therapeutic cancer vaccines: advancements, challenges and prospects

Fan,

Zhang,

Yang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades. Recently, therapeutic cancer vaccines have shown promise by eliciting de novo T cell responses targeting tumor antigens, including tumor-associated antigens and tumor-specific antigens. The objective was to amplify and diversify the intrinsic repertoire of tumor-specific T cells. However, the complete realization of these capabilities remains an ongoing pursuit. Therefore, we provide an overview of the current landscape of cancer vaccines in this review. The range of antigen selection, antigen delivery systems development the strategic nuances underlying effective antigen presentation have pioneered cancer vaccine design. Furthermore, this review addresses the current status of clinical trials and discusses their strategies, focusing on tumor-specific immunogenicity and anti-tumor efficacy assessment. However, current clinical attempts toward developing cancer vaccines have not yielded breakthrough clinical outcomes due to significant challenges, including tumor immune microenvironment suppression, optimal candidate identification, immune response evaluation, and vaccine manufacturing acceleration. Therefore, the field is poised to overcome hurdles and improve patient outcomes in the future by acknowledging these clinical complexities and persistently striving to surmount inherent constraints.

show abstract

Section: Cell-based Vaccinementioning

confidence: 99%

“… 149 DC vaccines can augment the immune response and improve tumor control with the help of ICI or adoptive T cells. 150 , 151 …”

Section: Vaccine Constituent and Platformmentioning

confidence: 99%